Ovid Therapeutics Inc. Operating Cash Flow
Ovid Therapeutics Inc. (OVID) reported Operating Cash Flow of -$31.49 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-13
- Ovid Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$17.59M.
- Ovid Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$13.90M.
- Ovid Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$10.41M.
- Ovid Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$12.87M.
- Ovid Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$38.33M.
- Ovid Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$55.96M.
- Ovid Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$45.78M.
- Ovid Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$55.23M, a 146.56% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$17.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$31.49M 10-Q · filed 2026-08-13 | -$41.90M derived: sum of 3 quarters · filed 2026-08-13 | -$54.77M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | -$13.90M 10-Q · filed 2026-05-12 | -$24.31M derived: sum of 2 quarters · filed 2026-05-12 | -$37.18M derived: sum of 3 quarters · filed 2026-05-12 | -$41.95M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | -$10.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | -$23.28M derived: sum of 2 quarters · filed 2026-03-18 | -$28.05M derived: sum of 3 quarters · filed 2026-08-13 | -$38.33M 10-K · filed 2026-03-18 | ||||
| 2025-09-30 | -$12.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$17.65M derived: sum of 2 quarters · filed 2026-08-13 | -$27.93M 10-Q · filed 2025-11-12 | -$37.93M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | -$4.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$15.05M 10-Q · filed 2026-08-13 | -$25.06M derived: sum of 3 quarters · filed 2026-08-13 | -$40.07M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | -$10.28M 10-Q · filed 2026-05-12 | -$20.29M derived: sum of 2 quarters · filed 2026-05-12 | -$35.30M derived: sum of 3 quarters · filed 2026-05-12 | -$49.55M derived: sum of 4 quarters · filed 2026-05-12 | ||||
| 2024-12-31 | -$10.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | -$25.02M derived: sum of 2 quarters · filed 2026-03-18 | -$39.27M derived: sum of 3 quarters · filed 2026-03-18 | -$55.96M 10-K · filed 2026-03-18 | ||||
| 2024-09-30 | -$15.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$29.26M derived: sum of 2 quarters · filed 2025-11-12 | -$45.95M 10-Q · filed 2025-11-12 | -$57.86M derived: sum of 4 quarters · filed 2025-11-12 | ||||
| 2024-06-30 | -$14.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$30.94M 10-Q · filed 2025-08-13 | -$42.85M derived: sum of 3 quarters · filed 2025-08-13 | -$52.90M derived: sum of 4 quarters · filed 2025-08-13 | ||||
| 2024-03-31 | -$16.69M 10-Q · filed 2025-05-13 | -$28.60M derived: sum of 2 quarters · filed 2025-05-13 | -$38.65M derived: sum of 3 quarters · filed 2025-05-13 | -$50.35M derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | -$11.91M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | -$21.96M derived: sum of 2 quarters · filed 2025-03-11 | -$33.67M derived: sum of 3 quarters · filed 2025-03-11 | -$45.78M 10-K · filed 2025-03-11 | -$45.78M 10-K · filed 2024-03-08 | |||
| 2023-09-30 | -$10.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$21.76M derived: sum of 2 quarters · filed 2024-11-12 | -$33.87M 10-Q · filed 2024-11-12 | -$33.87M 10-Q · filed 2023-11-03 | -$43.05M derived: sum of 4 quarters · filed 2024-11-12 | |||
| 2023-06-30 | -$11.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$23.82M 10-Q · filed 2024-08-13 | -$23.82M 10-Q · filed 2023-08-04 | -$32.99M derived: sum of 3 quarters · filed 2024-08-13 | -$45.67M derived: sum of 4 quarters · filed 2024-08-13 | |||
| 2023-03-31 | -$12.11M 10-Q · filed 2024-05-14 | -$12.11M 10-Q · filed 2023-05-05 | -$21.29M derived: sum of 2 quarters · filed 2024-05-14 | -$33.96M derived: sum of 3 quarters · filed 2024-05-14 | -$47.25M derived: sum of 4 quarters · filed 2024-05-14 | |||
| 2022-12-31 | -$9.18M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | -$21.85M derived: sum of 2 quarters · filed 2024-03-08 | -$35.14M derived: sum of 3 quarters · filed 2024-03-08 | -$55.23M 10-K · filed 2024-03-08 | ||||
| 2022-09-30 | -$12.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$25.96M derived: sum of 2 quarters · filed 2023-11-03 | -$46.05M 10-Q · filed 2023-11-03 | -$58.05M derived: sum of 4 quarters · filed 2023-11-03 | ||||
| 2022-06-30 | -$13.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | -$33.38M 10-Q · filed 2023-08-04 | -$45.37M derived: sum of 3 quarters · filed 2023-08-04 | -$56.25M derived: sum of 4 quarters · filed 2023-08-04 | ||||
| 2022-03-31 | -$20.09M 10-Q · filed 2023-05-05 | -$32.08M derived: sum of 2 quarters · filed 2023-05-05 | -$42.96M derived: sum of 3 quarters · filed 2023-05-05 | -$62.37M derived: sum of 4 quarters · filed 2023-05-05 | ||||
| 2021-12-31 | -$12.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13 | -$22.87M derived: sum of 2 quarters · filed 2023-03-13 | -$42.29M derived: sum of 3 quarters · filed 2023-03-13 | $118.61M 10-K · filed 2023-03-13 | ||||
| 2021-09-30 | -$10.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$30.29M derived: sum of 2 quarters · filed 2022-11-08 | $130.61M 10-Q · filed 2022-11-08 | $116.10M derived: sum of 4 quarters · filed 2022-11-08 | ||||
| 2021-06-30 | -$19.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $141.48M 10-Q · filed 2022-08-09 | $126.97M derived: sum of 3 quarters · filed 2022-08-09 | $125.50M derived: sum of 4 quarters · filed 2022-08-09 | ||||
| 2021-03-31 | $160.90M 10-Q · filed 2022-05-10 | $146.39M derived: sum of 2 quarters · filed 2022-05-10 | $144.92M derived: sum of 3 quarters · filed 2022-05-10 | $127.73M derived: sum of 4 quarters · filed 2022-05-10 | ||||
| 2020-12-31 | -$14.51M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | -$15.98M derived: sum of 2 quarters · filed 2022-03-15 | -$33.17M derived: sum of 3 quarters · filed 2022-03-15 | -$51.58M 10-K · filed 2022-03-15 | ||||
| 2020-09-30 | -$1.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$18.66M derived: sum of 2 quarters · filed 2021-11-10 | -$37.07M 10-Q · filed 2021-11-10 | -$53.96M derived: sum of 4 quarters · filed 2021-11-10 | ||||
| 2020-06-30 | -$17.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$35.61M 10-Q · filed 2021-08-16 | -$52.49M derived: sum of 3 quarters · filed 2021-08-16 | -$61.99M derived: sum of 4 quarters · filed 2021-08-16 | ||||
| 2020-03-31 | -$18.41M 10-Q · filed 2021-05-13 | -$35.30M derived: sum of 2 quarters · filed 2021-05-13 | -$44.79M derived: sum of 3 quarters · filed 2021-05-13 | -$56.64M derived: sum of 4 quarters · filed 2021-05-13 | ||||
| 2019-12-31 | -$16.89M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | -$26.38M derived: sum of 2 quarters · filed 2021-03-15 | -$38.22M derived: sum of 3 quarters · filed 2021-03-15 | -$51.09M 10-K · filed 2021-03-15 | ||||
| 2019-09-30 | -$9.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | -$21.34M derived: sum of 2 quarters · filed 2020-11-13 | -$34.20M 10-Q · filed 2020-11-13 | -$45.17M derived: sum of 4 quarters · filed 2020-11-13 | ||||
| 2019-06-30 | -$11.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$24.71M 10-Q · filed 2020-08-10 | -$35.67M derived: sum of 3 quarters · filed 2020-08-10 | -$45.72M derived: sum of 4 quarters · filed 2020-08-10 | ||||
| 2019-03-31 | -$12.87M 10-Q · filed 2020-05-07 | -$23.83M derived: sum of 2 quarters · filed 2020-05-07 | -$33.88M derived: sum of 3 quarters · filed 2020-05-07 | -$45.50M derived: sum of 4 quarters · filed 2020-05-07 | ||||
| 2018-12-31 | -$10.97M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | -$21.01M derived: sum of 2 quarters · filed 2020-03-11 | -$32.63M derived: sum of 3 quarters · filed 2020-03-11 | -$45.56M 10-K · filed 2020-03-11 | ||||
| 2018-09-30 | -$10.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | -$21.67M derived: sum of 2 quarters · filed 2019-11-08 | -$34.59M 10-Q · filed 2019-11-08 | -$43.60M derived: sum of 4 quarters · filed 2019-11-08 | ||||
| 2018-06-30 | -$11.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | -$24.55M 10-Q · filed 2019-08-07 | -$33.55M derived: sum of 3 quarters · filed 2019-08-07 | -$42.87M derived: sum of 4 quarters · filed 2019-08-07 | ||||
| 2018-03-31 | -$12.93M 10-Q · filed 2019-05-07 | -$21.93M derived: sum of 2 quarters · filed 2019-05-07 | -$31.25M derived: sum of 3 quarters · filed 2019-05-07 | |||||
| 2017-12-31 | -$9.01M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | -$18.33M derived: sum of 2 quarters · filed 2019-03-07 | -$31.47M 10-K · filed 2019-03-07 | |||||
| 2017-09-30 | -$9.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$22.46M 10-Q · filed 2018-11-08 | ||||||
| 2017-06-30 | -$13.14M 10-Q · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |